source
- Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomaNovo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.BioPharma Dive · 5d ago↗ source
- Lilly’s $3.8B psychedelics bet won’t open the M&A floodgatesEli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…BioSpace · 5d ago↗ source
- Summit has less than a year of cash runway left as PD-1/VEGF verdict nearsSummit’s star asset is the PD-1/VEGF bispecific ivonescimab, which this week produced promising survival data from a late-stage global trial in non-small cell lung cancer. The FDA review is ongoing…